Pfreundschuh M, Poeschel V, Zeynalova S et al.: Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial
Pfreundschuh-2014-JCO 2013 54 6861SMARTE
Adobe Acrobat Dokument 215.1 KB
Held G, Murawski N, Ziepert M et al.: Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol32:1112-1118, 2014;
JCO-2014-Held-1112-8 Role of Radiotherap
Adobe Acrobat Dokument 167.7 KB
Glass B, Hasenkamp J, Wulf G et al.: Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an
757.pdf
Adobe Acrobat Dokument 418.0 KB
Hohloch K, Zwick C, Ziepert M et al.: Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy i
Springer plus 3.5.pdf
Adobe Acrobat Dokument 299.8 KB
Seymour JF, Pfreundschuh M, Trneny M et al.: R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica, 2014;
R CHOP with or.pdf
Adobe Acrobat Dokument 1.2 MB
Meissner J, Tichy D, Dietrich S et al.: Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma. Br J Haematol, 2014;
Parenthood.pdf
Adobe Acrobat Dokument 87.8 KB
Assmann G, Shihadeh K, Poeschel V et al.: Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study. PLoS One 9:e88177, 20
Prevalence.pdf
Adobe Acrobat Dokument 326.7 KB